Methods and compositions for the inhibition of TRPV4
TRPV4 activation increases vascular permeability and can be triggered by both chemical and mechanical cues. This activation of TRPV4 can contribute to a number of pathological conditions, e.g., edema, inflammation, hypertension, and/or hyperalgesia. Described herein are methods and compositions relating to inhibition of mechanically-induced TRPV4 activation, e.g., for the treatment of pulmonary edema, edema, inflammation, hypertension, and/or hyperalgesia.
1. A viral vector comprising an isolated nucleic acid encoding a polypeptide:
a) the polypeptide comprising a sequence with at least 95% identity to the sequence of SEQ ID NO: 1, wherein the polypeptide comprises no more than 100 amino acids; and
b) wherein the polypeptide is capable of inhibiting the binding of Transient Receptor Potential Vanilloid 4 (TRPV4) or integrin to Cluster of Differentiation 98 (CD98).
2. The viral vector of claim 1 , wherein the nucleic acid is a cDNA.
3. The viral vector of claim 1 , wherein the polypeptide comprises the sequence of SEQ ID NO: 1.
4. The viral vector of claim 1 , wherein the viral vector is an adeno-associated virus (AAV) vector.